Predictive Effect of CA125 on Adverse Cardiovascular Events in Patients with Chronic Heart Failure

Abstract

Objective: To study the expression of CA125 in the serum of patients with CHF and the relationship between CA125 level and the occurrence of adverse cardiovascular events. Methods: The clinical data of 132 patients with CHF admitted to Shizuishan Second People’s Hospital from January 2023 to December 2023 were collected and divided into heart function II group, heart function III group, heart function IV group according to cardiac function. 44 healthy subjects who underwent physical examination during the same period were selected as the control group. The clinical data of CA125, NT-proBNP, echocardiography and other clinical data of the four groups were compared, and the incidence of major adverse cardiovascular events was followed up for 12 months. Results: Compared with the control group, the CA125 level in the CHF group was significantly increased (P < 0.05). In CHF patients, CA125, NT-proBNP, and LVEDD levels were positively correlated with cardiac function grade, and LVEF was negatively correlated with cardiac function grade (P < 0.05). The mortality rate and re-hospitalization rate of the group with CA125 serum concentration greater than 35 U/ml were significantly increased (P < 0.05). Conclusion: Serum CA125 level is related to the cardiac function level in CHF patients and increases with the deterioration of cardiac function. The increase of the index is related to the mortality rate and re-hospitalization rate, suggesting that CA125 can be used as an indicator to reflect the severity of heart failure and prognosis monitoring.